Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
COVID-19 vaccination: the VOICE for patients with cancer.
van der Veldt AAM, Oosting SF, Dingemans AC, Fehrmann RSN, GeurtsvanKessel C, Jalving M, Rimmelzwaan GF, Kvistborg P, Blank CU, Smit EF, Lemmens VEEP, Hiltermann TJN, Koopmans MPG, Huckriede ALW, Rots NY, van Els CACM, van Baarle D, Haanen JBAG, de Vries EGE. van der Veldt AAM, et al. Among authors: hiltermann tjn. Nat Med. 2021 Apr;27(4):568-569. doi: 10.1038/s41591-021-01240-w. Nat Med. 2021. PMID: 33589821 No abstract available.
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.
Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, Oosting SF, Schröder CP, Hiltermann TJN, van der Wekken AJ, Groen HJM, Kwee TC, Elias SG, Gietema JA, Bohorquez SS, de Crespigny A, Williams SP, Mancao C, Brouwers AH, Fine BM, de Vries EGE. Bensch F, et al. Among authors: hiltermann tjn. Nat Med. 2018 Dec;24(12):1852-1858. doi: 10.1038/s41591-018-0255-8. Epub 2018 Nov 26. Nat Med. 2018. PMID: 30478423 Clinical Trial.
Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica.
van der Geest KSM, Sandovici M, Rutgers A, Hiltermann TJN, Oosting SF, Slart RHJA, Brouwer E. van der Geest KSM, et al. Among authors: hiltermann tjn. Ann Rheum Dis. 2022 Oct;81(10):e210. doi: 10.1136/annrheumdis-2020-217381. Epub 2020 Apr 2. Ann Rheum Dis. 2022. PMID: 32241799 Free PMC article. No abstract available.
Management of immune checkpoint inhibitor-induced polymyalgia rheumatica.
van der Geest KSM, Sandovici M, Rutgers A, Hiltermann TJN, Oosting SF, Slart RHJA, Brouwer E. van der Geest KSM, et al. Among authors: hiltermann tjn. Ann Rheum Dis. 2022 Dec;81(12):e263. doi: 10.1136/annrheumdis-2020-218276. Epub 2020 Sep 4. Ann Rheum Dis. 2022. PMID: 32887684 No abstract available.
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial.
Oosting SF, van der Veldt AAM, GeurtsvanKessel CH, Fehrmann RSN, van Binnendijk RS, Dingemans AC, Smit EF, Hiltermann TJN, den Hartog G, Jalving M, Westphal TT, Bhattacharya A, van der Heiden M, Rimmelzwaan GF, Kvistborg P, Blank CU, Koopmans MPG, Huckriede ALW, van Els CACM, Rots NY, van Baarle D, Haanen JBAG, de Vries EGE. Oosting SF, et al. Among authors: hiltermann tjn. Lancet Oncol. 2021 Dec;22(12):1681-1691. doi: 10.1016/S1470-2045(21)00574-X. Epub 2021 Nov 9. Lancet Oncol. 2021. PMID: 34767759 Free PMC article. Clinical Trial.
Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours.
Oosting SF, van der Veldt AAM, Fehrmann RSN, GeurtsvanKessel CH, van Binnendijk RS, Dingemans AC, Smit EF, Hiltermann TJN, den Hartog G, Jalving M, Westphal TT, Bhattacharya A, de Wilt F, Boerma A, van Zijl L, Rimmelzwaan GF, Kvistborg P, van Els CACM, Rots NY, van Baarle D, Haanen JBAG, de Vries EGE. Oosting SF, et al. Among authors: hiltermann tjn. Lancet Oncol. 2022 Jul;23(7):833-835. doi: 10.1016/S1470-2045(22)00203-0. Epub 2022 Apr 25. Lancet Oncol. 2022. PMID: 35483383 Free PMC article. No abstract available.
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.
Zwierenga F, van Veggel B, Hendriks LEL, Hiltermann TJN, Hiddinga BI, Hijmering Kappelle LBM, Ter Elst A, Hashemi SMS, Dingemans AC, van der Leest C, de Langen AJ, van den Heuvel MM, van der Wekken AJ. Zwierenga F, et al. Among authors: hiltermann tjn. Lung Cancer. 2022 Aug;170:133-140. doi: 10.1016/j.lungcan.2022.06.012. Epub 2022 Jun 23. Lung Cancer. 2022. PMID: 35777160 Free article. Clinical Trial.
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer.
Gijtenbeek RGP, van der Noort V, Aerts JGJV, Staal-van den Brekel JA, Smit EF, Krouwels FH, Wilschut FA, Hiltermann TJN, Timens W, Schuuring E, Janssen JDJ, Goosens M, van den Berg PM, de Langen AJ, Stigt JA, van den Borne BEEM, Groen HJM, van Geffen WH, van der Wekken AJ. Gijtenbeek RGP, et al. Among authors: hiltermann tjn. ERJ Open Res. 2022 Oct 17;8(4):00239-2022. doi: 10.1183/23120541.00239-2022. eCollection 2022 Oct. ERJ Open Res. 2022. PMID: 36267895 Free PMC article.
Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer.
Muller M, Best MG, van der Noort V, Hiltermann TJN, Niemeijer AN, Post E, Sol N, In 't Veld SGJG, Nogarede T, Visser L, Schouten RD, van den Broek D, Hummelink K, Monkhorst K, de Langen AJ, Schuuring E, Smit EF, Groen HJM, Wurdinger T, van den Heuvel MM. Muller M, et al. Among authors: hiltermann tjn. Tumour Biol. 2024;46(s1):S327-S340. doi: 10.3233/TUB-220037. Tumour Biol. 2024. PMID: 37270827 Free article.
98 results